3.54

6.10% -0.23

After Hours: 3.54

Aardvark Therapeutics Inc (AARD)

Overview News Price History Discussions Forecast

Aardvark Therapeutics Inc stock is traded at $3.54, with a volume of 249.16K. It is down -6.10% in the last 24 hours and down -71.41% over the past month. Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Previous Close:

$3.77

Open:

$3.88

24h Volume:

249.16K

Relative Volume:

0.89

Market Cap:

$77.23M

Revenue:

Net Income/Loss:

$-57.59M

P/E Ratio:

-1.3366

EPS:

-2.6486

Net Cash Flow:

$-54.27M

1W Performance:

-27.46%

1M Performance:

-71.41%

6M Performance:

-72.06%

1Y Performance:

-61.06%

1-Day Range:

$3.52

$3.88

1-Week Range:

$3.52

$4.98

52-Week Range:

$3.52

$17.94

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Name

Aardvark Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(858) 225-7696

Address

4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

AARD's Discussions on Twitter

Compare AARD vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AARD Aardvark Therapeutics Inc	3.54	82.24M	0	-57.59M	-54.27M	-2.6486
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-02-26	Downgrade	Stifel	Buy → Hold
Jan-28-26	Initiated	B. Riley Securities	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy
Nov-07-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Stifel	Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Initiated	BofA Securities	Buy
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight
Mar-10-25	Initiated	Morgan Stanley	Overweight
Mar-10-25	Initiated	RBC Capital Mkts	Outperform

View All

Aardvark Therapeutics Inc Stock (AARD) Latest News

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Compare AARD vs VRTX, REGN, ALNY, ARGX, INSM

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Aardvark Therapeutics Inc Stock (AARD) Latest News

Decliners Report: Can Aardvark Therapeutics Inc outperform under higher oil prices2026 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn

Why is Aardvark Therapeutics stock sinking Monday? - MSN

Jones Trading cuts Aardvark Therapeutics stock price target on trial delay - Investing.com Australia

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark ... - Bluefield Daily Telegraph

Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com

Raymond James reiterates Aardvark Therapeutics stock rating on dosing path By Investing.com - Investing.com UK

Aardvark Therapeutics, Inc. Files Form 8-K Announcing Entry Into Material Definitive Agreement – Company Details, Nasdaq Symbol AARD, and Contact Information - Minichart

Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating - Investing.com

Cantor Fitzgerald reiterates Aardvark Therapeutics stock rating By Investing.com - Investing.com Canada

B.Riley cuts Aardvark Therapeutics stock price target on trial pause By Investing.com - Investing.com South Africa

BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat

Aardvark Therapeutics Inc. has officially signed an equity distribution agreement with Piper Sandler. - Bitget

Balancing Safety Concerns and Long-Term Opportunity: Justifying a Buy Rating on Aardvark Amid ARD-101 Clinical Risks - TipRanks

B.Riley cuts Aardvark Therapeutics stock price target on trial pause - Investing.com India

Aardvark Therapeutics Pauses Phase 3 Trials for ARD-101 in Prader-Willi Syndrome, Reports 2025 Financial Results and Pipeline Updates - Minichart

Aardvark Therapeutics Establishes $150 Million Equity Program - TipRanks

Aardvark Therapeutics (NASDAQ: AARD) launches $150M at-the-market stock program - Stock Titan

Aardvark Therapeutics Launches $150 Million ATM Equity Program With Piper Sandler - TradingView

Aardvark Therapeutics, Inc. – Clinical-Stage Biopharma Advancing TAS2R Small-Molecule Therapies for Obesity and Metabolic Diseases - Minichart

Aardvark Therapeutics Files $400 Million Mixed Shelf - marketscreener.com

Aardvark Therapeutics (AARD) registers $400M shelf; $150M ATM included - Stock Titan

Aardvark Therapeutics reports fourth quarter and full year 2025 financial results and provides business updates - marketscreener.com

Aardvark Therapeutics 10-K: $0 Revenue; $(2.93) EPS - TradingView

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget

Aardvark Therapeutics (AARD) halts ARD-101 PWS Phase 3 to probe cardiac signal - Stock Titan

AARD: Clinical trial pauses and strong cash reserves define the period, with guidance due in Q2 2026 - TradingView

Aardvark Therapeutics (NASDAQ: AARD) halts ARD-101 and ARD-201 trials as 2025 loss widens - Stock Titan

Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) EstimateAardvark Therapeutics (NASDAQ:AARD) - Benzinga

Aardvark halts obesity and PWS studies after reversible heart findings - Stock Titan

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Breakouts Watch: Can Aardvark Therapeutics Inc expand its profit margins2026 Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Investors to Inquire about Securities Investigation - ACCESS Newswire

If You Invested $1,000 in Aardvark Therapeutics (AARD) - Stock Titan

AARD SEC FilingsAardvark Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Aardvark’s ARD-101 Prader-Willi Study Suspended: What Investors Should Watch Next - TipRanks

Aardvark’s HERO Extension Trial Paused: What ARD-101’s Status Means for Investors - TipRanks

Aardvark Therapeutics, Inc. (AARD) - MSN

HC Wainwright & Co. downgrades Aardvark Therapeutics (AARD) - MSN

Earnings Recap: Can Aardvark Therapeutics Inc reach all time highs this year - baoquankhu1.vn

AARD stock slumps 54% pre-market – here’s why analysts are not comfortable with the suspension of a key phase 3 trial - MSN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent

Arcellx and Aardvark Therapeutics Compared - National Today

Analyzing Arcellx (NASDAQ:ACLX) and Aardvark Therapeutics (NASDAQ:AARD) - Defense World

Aug Wrap: Does Aardvark Therapeutics Inc have a competitive edge2026 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

Cresset Asset Management Invests $1.95M in Aardvark Therapeutics - National Today

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

New Highs: Should I trade or invest in Aardvark Therapeutics Inc2025 Market Outlook & Low Risk High Win Rate Picks - baoquankhu1.vn

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits

A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves - simplywall.st

Aardvark Therapeutics Inc Stock (AARD) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to AARD